Dare Bioscience (DARE) Capital Expenditures (2013 - 2025)
Dare Bioscience's (DARE) quarterly Capital Expenditures came in at $341626.0 in Q4 2025, down 34.9% YoY from $524761.0 in Q4 2024, and up 369.77% on a QoQ basis from $72722.0 in Q3 2025.
Dare Bioscience (DARE) Capital Expenditures (2013 - 2025) Analysis & Trends
Dare Bioscience (DARE) has 11 years of Capital Expenditures data on file, last reported at $341626.0 in Q4 2025.
- Quarterly Capital Expenditures fell 34.9% year-over-year to $341626.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $385278.0 (down 32.77% YoY) and the FY2025 annual result came in at $385278.0, down 32.77% from the prior year.
- Capital Expenditures grew to $341626.0 in Q4 2025, from $72722.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $524761.0 in Q4 2024 to a low of -$87891.0 in Q1 2022.
- A 5-year average of $54929.5 and a median of -$3799.0 in 2022 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2021 — Capital Expenditures sank 1587.89% — and 2024, when it soared 2474.59%.
- Tracing DARE's Capital Expenditures over 5 years: stood at -$35397.0 in 2021, then slumped by 80.87% to -$64022.0 in 2022, then soared by 65.48% to -$22099.0 in 2023, then soared by 2474.59% to $524761.0 in 2024, then tumbled by 34.9% to $341626.0 in 2025.
- The last three Capital Expenditures figures came in at $341626.0 (Q4 2025), $72722.0 (Q3 2025), and -$14535.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | Dare Bioscience | 12.36 Mn | -256,055.23 | -132,343.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 341,626.00 |
| Dec 31, 2025 | 341,626.00 |
| Sep 30, 2025 | 72,722.00 |
| Sep 30, 2025 | 72,722.00 |
| Jun 30, 2025 | -14,535.00 |
| Jun 30, 2025 | -14,535.00 |
| Mar 31, 2025 | -14,535.00 |
| Mar 31, 2025 | -14,535.00 |
| Dec 31, 2024 | 524,761.00 |
| Dec 31, 2024 | 524,761.00 |
| Sep 30, 2024 | 48,285.00 |
| Sep 30, 2024 | 48,285.00 |
| Jun 30, 2024 | -7,296.00 |
| Jun 30, 2024 | -7,296.00 |
| Mar 31, 2024 | 7,296.00 |
| Mar 31, 2024 | 7,296.00 |
| Dec 31, 2023 | -22,099.00 |
| Dec 31, 2023 | -22,099.00 |
| Sep 30, 2023 | -18,896.00 |
| Sep 30, 2023 | -18,896.00 |